BioCentury | Mar 28, 2016
Product Development

Accelerating the Accelerator

...prime-boost vaccine regimen with the pharma's AdVac adenoviral vector technology. Janssen is also collaborating with UbiVac LLC...
...Johnson (NYSE:JNJ), New Brunswick, N.J. MiRXES Pte. Ltd., Singapore Queensland University of Technology, Brisbane, Australia UbiVac LLC...
...of Technology Investigate HPV-driven oropharyngeal cancer to find novel biomarkers for early disease stages Mar-16 UbiVac LLC...
BioCentury | Oct 19, 2015
Company News

UbiVac, J&J deal

...Johnson’s Janssen Biotech Inc. unit partnered with UbiVac to develop preclinical and clinical versions of UbiVac’s...
...to develop preclinical and clinical versions of UbiVac’s DRibble immunotherapy technology to treat oral cancer. UbiVac...
...manufacturing milestones. Janssen will fund the research and have an option to license the technology. UbiVac’s...
Items per page:
1 - 2 of 2
BioCentury | Mar 28, 2016
Product Development

Accelerating the Accelerator

...prime-boost vaccine regimen with the pharma's AdVac adenoviral vector technology. Janssen is also collaborating with UbiVac LLC...
...Johnson (NYSE:JNJ), New Brunswick, N.J. MiRXES Pte. Ltd., Singapore Queensland University of Technology, Brisbane, Australia UbiVac LLC...
...of Technology Investigate HPV-driven oropharyngeal cancer to find novel biomarkers for early disease stages Mar-16 UbiVac LLC...
BioCentury | Oct 19, 2015
Company News

UbiVac, J&J deal

...Johnson’s Janssen Biotech Inc. unit partnered with UbiVac to develop preclinical and clinical versions of UbiVac’s...
...to develop preclinical and clinical versions of UbiVac’s DRibble immunotherapy technology to treat oral cancer. UbiVac...
...manufacturing milestones. Janssen will fund the research and have an option to license the technology. UbiVac’s...
Items per page:
1 - 2 of 2